ArticleWorld journal of gastroenterology2020
Neoadjuvant chemotherapy
Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Is neoadjuvant chemotherapy followed by surgery the appropriate treatment for esophagogastric signet ring cell carcinomas? A systematic review and meta-analysis.Frontiers in surgery · 2024Pooled it
- Clinicopathological Features and Prognostic-Related Risk Factors of Gastric Signet Ring Cell Carcinoma: A Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- The impact of adjuvant chemotherapy on overall survival and cancer-specific survival in patients with extrahepatic cholangiocarcinoma across different age groups: a population-based study.Journal of gastrointestinal oncology · 2026Article
- Article
- Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Gastric Signet-Ring Cell Carcinoma.Cancers · 2025Article
- Adolescents and young adults with germline CDH1 variants and the risk of overtreatment.Journal of the National Cancer Institute · 2025Article
- Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Mapping the landscape of gastric signet ring cell carcinoma: Overcoming hurdles and charting new paths for advancement.World journal of clinical oncology · 2025Article
- Upfront surgery versus chemotherapy neoadjuvant in the survival of patients with locally advanced gastric signet-ring-cell adenocarcinoma. A scoping review.Ecancermedicalscience · 2025Review
- Development and validation of a nomogram for predicting survival in gastric signet ring cell carcinoma patients treated with radiotherapy.Scientific reports · 2024Article
- Clinicopathological features and survival outcomes for gastric adenocarcinoma: Real-world single-center data.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Perioperative chemotherapy improves survival of patients with locally advanced diffuse gastric cancer.World journal of gastrointestinal surgery · 2024Article
- Multimodal Therapy Versus Primary Surgery for Gastric and Gastroesophageal Junction Diffuse Type Carcinoma, with a Focus on Signet Ring Cell Carcinoma: A Nationwide Study.Annals of surgical oncology · 2024Article
- Article
- The inaccuracies of gastric adenocarcinoma clinical staging and its predictive factors.Journal of surgical oncology · 2023Article
- Survival Outcome of Gastric Signet Ring Cell Carcinoma Based on the Optimal Number of Examined Lymph Nodes: A Nomogram- and Machine-Learning-Based Approach.Journal of clinical medicine · 2023Article
- Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.Cancer medicine · 2023Article
- An Evaluation of Fluorouracil plus Paclitaxel and Oxiliplatin as a First-Line Treatment for Advanced Gastric Squamous Cell Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma.World journal of clinical cases · 2022Article
- Survival of patients with gastric cancer surgically treated at the National Cancer Center of China from 2011 to 2018 according to stage at diagnosis.Journal of the National Cancer Center · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of neoadjuvant chemotherapy for patients with signet-ring cell carcinoma of the stomach is controversial.
aimTo evaluate the perioperative and long-term outcomes of neoadjuvant chemotherapy for locally advanced gastric signet-ring cell carcinoma.
methodsThis retrospective study identified patients with locally advanced signet-ring cell carcinomas of the stomach (cT3/4 and cN any) diagnosed from January 2012 to December 2017 by using the clinical Tumor-Node-Metastasis (cTNM) staging system. We performed 1:1 propensity score matching (PSM) to reduce bias in patient selection. The histologic and prognostic effects of neoadjuvant chemotherapy were assessed. The overall survival rates were used as the outcome measure to compare the efficacy of neoadjuvant chemotherapy
resultsOf the 144 patients eligible for this study, 36 received neoadjuvant chemotherapy, and 108 received initial surgery after diagnosis. After adjustment by PSM, 36 pairs of patients were generated, and baseline characteristics, including age, sex, American Society of Anesthesiologists score, tumor location, and cTNM stage, were similar between the two groups. The R0 resection rates were 88.9% and 86.1% in the surgery-first and neoadjuvant chemotherapy groups after PSM, respectively (
conclusionNeoadjuvant chemotherapy provides no survival benefit in patients with locally advanced gastric signet-ring cell carcinoma. For resectable gastric signet-ring cell carcinoma, upfront surgery should be the primary therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.